RxDoctor Payments Data

Aaron Rubenstein, PA

Physician Assistant · Marlton, NJNPI 1194363234

Payments from drug & device makers

$5,049in general payments, 2019–2025

Across 303 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$707
  • Regeneron Healthcare Solutions, Inc.$405
  • Sanofi$347
  • Verona Pharma, Inc.$325
  • Takeda Pharmaceuticals U.S.A., Inc.$318
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$4,92698%
  • Education$1232%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,049 in reported general payments places this provider in the 90th percentile of 2,726 physician assistant providers in New Jersey.

See all physician assistant providers in New Jersey

Medicare billing

Part B allowed, 2024
$34,559
Medicare patients
285
Services billed
335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter161$147,361
Breo ElliptaFluticasone/Vilanterol93$47,600
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$13,447
Spiriva RespimatTiotropium Bromide13$13,385
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$11,999
Stiolto RespimatTiotropium Br/Olodaterol Hcl25$11,740
Advair HfaFluticasone Propion/Salmeterol17$8,357
Roflumilast11$7,400
SymbicortBudesonide/Formoterol Fumarate19$7,306
Combivent RespimatIpratropium/Albuterol Sulfate11$6,979
Albuterol Sulfate HfaAlbuterol Sulfate192$6,701
Fluticasone-SalmeterolFluticasone Propion/Salmeterol41$6,243
Incruse ElliptaUmeclidinium Bromide17$5,907
Arnuity ElliptaFluticasone Furoate15$3,710
Varenicline Tartrate15$3,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$1,082$216,578306 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$16$32,10549 claims
AstraZenecaBreztri Aerosphere, Symbicort$707$20,75437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,726 physician assistant providers in New Jersey.

Other physician assistant in Marlton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →